Longeveron Inc. 2024 Q1 Form 10-Q Summary
Business context and reporting period
Longeveron is a clinical-stage biotechnology company developing Lomecel-B™ cellular therapies for hypoplastic left heart syndrome, Alzheimer’s disease and aging-related frailty. The company has no FDA-approved product and generates revenue primarily from clinical trials, including Bahamas Registry Trials, contract manufacturing and grants. This unaudited Form 10-Q covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0.548 million | $0.279 million | Up 96% |
| Gross profit | $0.329 million | $0.076 million | Up $0.253 million |
| Gross margin | 60.0% | 27.2% | Up 32.8 percentage points |
| Operating expenses | $4.419 million | $4.792 million | Down 8% |
| Loss from operations | $4.090 million | $4.716 million | Improved $0.626 million |
| Net loss | $4.058 million | $4.647 million | Improved $0.589 million |
| Basic and diluted loss per share | $1.61 loss | $2.21 loss | Improved |
| Cash used in operating activities | $3.086 million | $5.848 million | Improved $2.762 million |
Clinical trial revenue increased to $0.515 million from $0.238 million, primarily due to increased participant demand for the Bahamas Registry Trial. Contract manufacturing revenue was $0.033 million versus none in the prior-year quarter. Grant revenue declined to zero from less than $0.1 million.
General and administrative expense increased 9% to $2.2 million, primarily due to higher professional fees. Research and development expense declined 20% to $2.2 million, reflecting lower Alzheimer’s trial costs, reduced aging-related frailty activity following the discontinuation of the Japan trial, lower manufacturing supply costs and lower equity-based compensation, partly offset by higher employee compensation and benefits.
At March 31, 2024, total assets were $9.697 million, including $1.940 million of cash and cash equivalents and $0.351 million of marketable securities. Current liabilities were $5.295 million, total liabilities were $6.656 million and stockholders’ equity was $3.041 million. The company reported no credit facility or other conventional debt; lease liabilities totaled approximately $1.896 million on a present-value basis.
Material changes versus the prior comparable period
- Revenue nearly doubled, driven by higher Bahamas Registry Trial participation and the addition of contract manufacturing revenue.
- Gross margin improved substantially because revenue increased faster than directly attributable costs.
- Operating expenses declined, mainly because of reduced clinical development spending, although G&A expense increased.
- Net loss narrowed by 13%, but the company continued to incur significant operating losses and had an accumulated deficit of approximately $89.0 million at March 31, 2024.
- Operating cash burn decreased to $3.1 million from $5.8 million, but cash and cash equivalents fell by $3.009 million during the quarter.
- The company completed a one-for-10 reverse stock split on March 26, 2024. Reported historical share and per-share data in the filing reflect the reverse split.
- The company discontinued its aging-related frailty clinical trial in Japan and reduced related spending and staffing, while continuing Bahamas registry activities and focusing strategically on HLHS and Alzheimer’s disease.
Guidance, outlook, risks and unusual items
Management stated that, following April 2024 financings, available cash is expected to fund operating expenses and capital expenditures into the fourth quarter of 2024. This estimate is subject to uncertainty, and the company has no committed credit facility or other committed source of capital.
The financial statements state that the company does not have sufficient cash to meet minimum expenditure commitments for one year from the date the financial statements were available for issuance. Accordingly, there is substantial doubt about the company’s ability to continue as a going concern. Management expects recurring operating losses to continue and intends to seek additional equity or debt financing, grants, partnerships, licensing transactions and other funding sources.
After quarter-end, the company raised approximately $5.25 million of gross proceeds, or $4.7 million net of placement agent fees, in an offering that closed April 10, 2024. It subsequently received approximately $6.2 million of gross proceeds, or $5.6 million net of placement agent fees, from a warrant inducement transaction that closed April 18, 2024. These transactions involved substantial warrant issuances and amendments, creating potential future dilution.
ELPIS II, the company’s randomized Phase 2b HLHS trial, was more than 60% enrolled, with management planning to complete enrollment in 2024, although timing is not assured. The company is pursuing potential strategic collaboration for the Alzheimer’s program. Product candidates remain investigational and require successful clinical development, regulatory approval, manufacturing scale-up and market acceptance.
Other disclosed obligations and contingencies include approximately $1.4 million of expected clinical research organization expenditures over the next two years, $1.9 million of operating lease obligations, accrued University of Miami milestone fees, and potential revenue-sharing obligations under an Alzheimer’s Association grant. The filing reports no material legal proceedings.
Important facts investors should verify
- Whether the April financings and warrant transactions provide sufficient runway beyond the fourth quarter of 2024.
- The terms, share count impact and potential dilution from the April offerings, amended warrants and new warrants.
- Actual enrollment progress, timing and clinical outcomes for the ELPIS II HLHS trial.
- Whether the company can obtain additional capital or strategic partnerships before available funds are exhausted.
- The sustainability and concentration of Bahamas Registry Trial revenue, which represented most Q1 2024 revenue and is not product-sale revenue.
- Regulatory, safety and efficacy risks for Lomecel-B™, including the absence of any FDA-approved product.
- The company’s stated going-concern uncertainty and the discrepancy between the balance-sheet cash figure of $1.940 million and the approximately $1.8 million cash figure cited in MD&A.